Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
PMID: 32675772
2020
Journal of acquired immune deficiency syndromes (1999)
Abstract: Participants with screening HIV-1 RNA <50 copies/mL for >=6 months; no prior virologic failure; and no documented resistance-associated major protease inhibitor, integrase inhibitor, nucleoside reverse transcriptase inhibitor (NRTI), or non-NRTI mutations or integrase resistance-associated substitution R263K were randomly assigned 1:1 to switch to once-daily dolutegravir 50 mg plus rilpivirine 25 mg on day 1 (early-switch group) or to continue their current antiretroviral regimen and, if virologically suppressed at week 48, switch to dolutegravir plus rilpivirine at week 52 (late-switch group) until week 148.
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
PMID: 30951600
2020
Journal of the Pediatric Infectious Diseases Society
Abstract: HIV-1 genotypic drug resistance testing was available at time of failure from 6 participants; 1 had evolution in integrase resistance with E138T, S147G, and R263K mutations at week 192 and phenotypic dolutegravir resistance of a 5.1-fold change.
Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
PMID: 31330378
2020
Journal of global antimicrobial resistance
Abstract: Before INSTI treatment one patient harboured the major INSTI-RM R263K and three patients the accessory INSTI-RMs T97A.
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
PMID: 31617907
2020
The Journal of antimicrobial chemotherapy
Abstract: Among the 29 relatively common INSTI-selected mutations, 24 emerged as candidates for inclusion on a list of INSTI surveillance drug-resistance mutations: T66A/I/K, E92G/Q, G118R, F121Y, E138A/K/T, G140A/C/S, Y143C/H/R/S, S147G, Q148H/R/K, N155H, S230R and R263K.
Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient.
Abstract: After several weeks, virological failure was confirmed with 4.01 HIV RNA Log copies/mL and R263K and M184V resistance mutations were detected.
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Result: The DTG resistance associated mutation R263K was not found.
Discussion: The E157Q substitution (found in subject 13) is a natural polymorphism described as a compensatory mutation for R263K-mediated DTG resistance and after RAL exposure.
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
PMID: 32105319
2020
The Journal of antimicrobial chemotherapy
Abstract: Two had Q148K minority variants and two had R263K (one of whom also had L74I).
Result: Two had Q148K and two had R263K minority variants (one of whom also had L74I).
Discussion: One individual out of 115 had both L74I and the signature dolutegravir mutation R263K detected by next-generation sequencing, though R263K was a minority variant.
Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
Result: Only one mutation, R263K, was in the list of SDRMs.
Result: Two of the patients had major mutations, including R263K (1/183; 0.5%), which was associated with intermediate-level DTG, EVG resistance, and low-level RAL, BIC resistance, and unusual mutation in DR-position S147T, which does not reduce susceptibility to any INSTI.
Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.
PMID: 32929472
2020
The Journal of antimicrobial chemotherapy
Abstract: Only three (1.7%) subjects had INSTI TDR (R263K, E138K and G163R), while minority variants with integrase TDR were detected in 9.6% of subjects.
Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation.
Result: This resistance test newly revealed the E138K, Q148R, and R263K INSTI mutations at frequencies of 100% by means of next-generation sequencing (NGS), causing high-level resistance to RAL, EVG, DTG, and BIC.
HIV mutation literature information.
PMID: 
2020
Journal of acquired immune deficiency syndromes (1999)
Browser Board
Co-occurred Entities
Filtrator
ViMRT